OakChart

Quoin Pharmaceuticals Ltd ADR

QNRXHealthcare·Biotechnology·USA·Nano·NASD·Nov 11 • 3:57 PM ET

3.76+0.03 (0.80%)
2026-11-12 06:00 CET
Market cap
18.06 USD m
Revenue, TTM
0.00 USD m
Net income, TTM
-19.65 USD m
Free cash flow, TTM
-18.89 USD m
EPS diluted, TTM
-9.14
P/E
-
Compare

Price

QNRX against its 20, 50 and 200-day averages
2050200beatmiss
4.006.008.0010.0015.5M31.0MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26QNRXclose 3.7620-day 3.9850-day 5.14200-day 5.813.7652w low

84.0% under the 52-week high of 23.50 on 25 Nov 2025. 52-week low 3.25 on 23 Jun 2026. Last 15 sessions, 33.9% high to low

Volume 0.01× normal · the line is the 50-bar volume average

Profile

QNRX
52-week range, 3% of the way up
3.2523.50

Quoin Pharmaceuticals Ltd. engages in the development of therapeutic products for the treatment of rare and orphan diseases. Its product pipeline includes QRX003, QRX004, QRX007, and QRX008. The company was founded by Michael Myers and Denise Carter on March 5, 2018 and is headquartered in Ashburn, VA.

Employees4
IPOJul 29, 2016
Beta1.65
ATR, 14d0.34
Rel volume0.01
Inst own30.80%

Snapshot

6 groups

Valuation

Index-
Market Cap18.05M
Enterprise Value-15.13M
Income-19.65M
Sales0.00M
Book/sh5.97
Cash/sh6.91
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees4
IPOJul 29, 2016

Ratios

P/E-
Forward P/E-
PEG-
P/S-
P/B0.63
P/C0.54
P/FCF-
EV/EBITDA-
EV/Sales-
Quick Ratio7.20
Current Ratio7.20
Debt/Eq0.00
LT Debt/Eq0.00
Option/ShortNo / Yes

Earnings

EPS (ttm)-9.14
EPS next Y-2.42
EPS next Q-0.91
EPS this Y65.17%
EPS next Y53.05%
EPS next 5Y52.46%
EPS past 3/5Y2.37% 61.71%
Sales past 3/5Y- -
EPS Y/Y TTM98.98%
Sales Y/Y TTM-
EPS Q/Q85.80%
Sales Q/Q-
EarningsNov 05 BMO
EPS/Sales Surpr.36.00% -

Ownership

Insider Own-
Insider Trans-
Inst Own30.80%
Inst Trans6.54%
ROA-95.47%
ROE-143.02%
ROIC-68.48%
Gross Margin-
Oper. Margin-
Profit Margin-
SMA20-5.64%
SMA50-26.85%
SMA200-35.26%
Trades-

Technical

Shs Outstand4.80M
Shs Float-
Short Float-
Short Ratio0.04
Short Interest0.02M
52W High23.50 -84.00%
52W Low3.25 15.69%
Volatility7.41% 6.94%
ATR (14)0.34
RSI (14)38.12
Beta1.65
Rel Volume0.01
Avg Volume536.23K
Volume4,430

Performance

Perf Week-6.47%
Perf Month-9.40%
Perf Quarter-37.85%
Perf Half Y-36.38%
Perf YTD-73.94%
Perf Year-67.33%
Perf 3Y-97.22%
Perf 5Y-99.99%
Perf 10Y-100.00%
Recom1.00
Target Price21.57
Prev Close3.73
Price3.76
Change %0.80%

Analyst ratings

latest 3 of 3
DateActionAnalystRating changeTargetImplied
Oct 19, 2026InitiatedCCanaccord GenuityBuy$18+378.7%
Oct 12, 2026InitiatedBBTIG ResearchBuy$14+272.3%
Sep 23, 2026InitiatedLLake StreetBuy$20+431.9%

Peers

Mkt cap
TickerCompanyMkt cap
AZTRAzitra Inc3.55M
PVLAPalvella Therapeutics Inc2.40B
ABEOAbeona Therapeutics Inc131.44M
DRMADermata Therapeutics Inc3.54M
KRYSKrystal Biotech Inc9.15B
TTRXTurn Therapeutics Inc323.15M
VRCAVerrica Pharmaceuticals Inc67.17M
ACRSAclaris Therapeutics Inc688.38M
ARQTArcutis Biotherapeutics Inc3.59B
CUVLClinuvel Pharmaceuticals Ltd ADR256.99M

Insider trading

4 filings
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Carter Denise P.Chief Operating OfficerAug 31 '26Buy4.8820,49099,99137,709Sep 01 09:40 PM
Myers MichaelChief Executive OfficerAug 31 '26Buy4.8820,49099,99137,713Sep 01 09:39 PM
Lawlor Sally BridgetChief Financial OfficerAug 31 '26Buy4.8810,24449,99110,684Sep 01 09:39 PM
Culverwell Anthony JamesDirectorAug 31 '26Buy4.886,14629,99240,364Sep 01 09:38 PM

News

latest 14 of 200
  • Quoin Pharmaceuticals' Latest NETHERTON NOW Video Details the Life of a Family Living with Netherton Syndrome (GlobeNewswire) -5.19%
  • Quoin Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2026 Financial Results (GlobeNewswire)
  • Quoin Pharmaceuticals Heads Into Q3 With A Flat Loss Bar And A Stock Near Its Lows (Earnings Whispers)
  • Quoin Pharmaceuticals to Announce Corporate Update and Third Quarter 2026 Financial Results on Thursday, November 5, 2026 (GlobeNewswire)
  • Quoin Pharmaceuticals Announces Publication of Peer-Reviewed Paper on QRX003 for Netherton Syndrome in Dermatology and Therapy (GlobeNewswire)
  • Quoin Pharmaceuticals Announces European Medicines Agency (EMA) Grants Orphan Drug Designation for QRX003 for the Treatment of Peeling Skin Syndrome (GlobeNewswire)
  • Quoin Pharmaceuticals Announces Acceptance of QRX003 Paper in Dermatology and Therapy (GlobeNewswire)
  • Four Small-Cap Stocks Report New Developments (CHGA, QNRX, MYSE, LNKS) (FinanceWire) -5.48%
  • Quoin Pharmaceuticals Announces FDA Fast Track Designation for QRX003 for the Treatment of Peeling Skin Syndrome (GlobeNewswire)
  • Quoin Pharmaceuticals Releases New NETHERTON NOW Video: Aminah's Story Featuring Laura Wright-Sexton, MD, the Physician Who First Met Her Daughter in the ICU (GlobeNewswire)
  • CORRECTION -- Quoin Pharmaceuticals Announces FDA Grants Rare Pediatric Disease Designation for QRX003 in Peeling Skin Syndrome (GlobeNewswire)
  • Quoin in line for second priority review voucher if rare paediatric drug approved (Pharmaceutical Technology)
  • Quoin in line for priority review voucher if rare paediatric drug approved (Pharmaceutical Technology)
  • Quoin Pharmaceuticals Announces FDA Grants Rare Pediatric Disease Designation for QRX003 in Peeling Skin Syndrome (GlobeNewswire)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-05-0.970-1.516-0.9700.000.007
2026Q22026-08-14-1.900-1.610-2.7200.000.004
2026Q12026-05-07-1.770-2.170-2.5410.000.003
2025Q42026-03-26-1.740-4.020-2.9200.000.002
2025Q32025-11-06-6.710-4.285-6.7440.00-2
2025Q22025-08-07-6.280-6.820-224.520.000.002
2025Q12025-05-13-6.500-7.175-225.680.000.002
2024Q42025-03-13-12.250-16.100-437.190.000.003
2024Q32024-11-07-16.450-15.400-571.780.00-2
2024Q22024-08-08-13.650-21.963-477.030.000.004
2024Q12024-05-09-38.850-26.600-1,3710.000.002
2023Q42024-03-13-72.800-81.025-2,5710.000.002
2023Q32023-11-08-68.250-95.316-2,3820.000.003
2023Q22023-08-02-74.550-99.400-0.5170.000.003
2023Q12023-05-08-142.8-113.4-0.9920.000.004
2022Q42023-03-08-172.2-215.6-1.2110.000.003

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2017FY-7,665-8,715-257,490--
2018FY-4,305--158,862--
2021FY-35,779-25,533-2,4900.000.00
2022FY-1,638-1,901-11.4240.000.00
2023FY-337.4-331.45-11,7810.000.00
2024FY-66.850-72.800-2,3530.000.00
2025FY-14.800-20.155-14.8500.000.00
2026FY--5.154--0.00
2027FY--2.420--0.00
2028FY--1.590--14.58
2029FY--0.045--40.76
2030FY-1.800--75.60

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-055000.000.000.00
2026Q4S2026-10-165000.000.000.00
2026Q4S2026-10-084000.000.000.00
2026Q4S2026-09-223000.000.000.00
2026Q4S2026-08-262000.000.000.00
2026Q4S2026-08-191000.000.000.00
2026Q4S2026-08-142000.000.000.00
2026Q4S2026-05-072000.000.000.00
2026Q4S2026-05-012000.000.000.00
2026Q4S2026-04-141000.000.000.00
2026Q4R2026-11-05211-0.60-0.65-0.54
2026Q4R2026-10-08210-1.38-2.14-0.61
2026Q4R2026-09-02110-0.61-0.61-0.61
2026Q4R2026-08-14110-0.77-0.77-0.77

Estimate history

EPS, annual-257489.552-158862.27-16307.065-1290.96-2490.265-11.424-11781.484-2352.813-10.632-9.1401
Period201720182019202020212022202320242025TTM
EPS, quarterly-571.775-437.194-225.684-224.522-6.744-2.92-2.541-2.72-0.958
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual0000000000
Period201720182019202020212022202320242025TTM
Sales, quarterly000000000
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual0000.0020.0181.6480.0010.0071.4984.804
Period201720182019202020212022202320242025MRQ
Shares, quarterly0.0040.0070.0170.5880.5881.4981.9612.0084.804
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue0.000.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.100.100.100.100.100.100.100.230.13
Gross Profit-0.10-0.10-0.10-0.10-0.10-0.10-0.10-0.23-0.13
Selling, General and Administrative Excl. Other20.0216.329.479.258.314.461.586.048.01
Research and Development12.769.783.523.202.561.460.143.403.76
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-20.12-16.42-9.57-9.35-8.41-4.57-1.68-6.27-8.13
Interest Expense0.000.000.000.000.71-1.190.410.00
Unusual Expense0.08-0.00-0.010.000.3116.910.43-1.96-2.55
Net Income Before Taxes-19.65-15.93-9.01-8.66-9.34-21.48-2.11-4.72-5.59
Income Taxes0.000.000.000.000.000.000.000.000.00
Consolidated Net Income-19.65-15.93-9.01-8.66-9.34-21.48-2.11-4.72-5.59
Net Income From Continuing Operations-19.65-15.93-9.01-8.66-9.34-21.48-2.11-4.72-5.59
Net Income-19.65-15.93-9.01-8.66-9.41-21.48-2.11-4.72-5.59
EPS (Recurring)-3.89-10.63-2,354.19-11,778.94-11.16-1,117.67-1,107.52-21,056.27-209,474.20
EPS (Basic, Before Extraordinaries)-9.14-10.63-2,352.81-11,781.48-11.42-2,490.26-1,290.96-16,307.07-158,862.27
EPS (Diluted)-9.14-10.63-2,352.81-11,781.48-11.42-2,490.26-1,290.96-16,307.07-158,862.27
EBITDA-20.02-16.32-9.47-9.25-8.31-4.46-1.58-6.04-8.01
Non-Operating Income (Expense)0.550.490.560.690.100.000.000.00-0.01
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense1.751.161.271.090.76-0.210.750.96
Shares Outstanding4.801.500.010.001.650.020.000.000.00
Market Capitalization18.0618.060.170.14983.08174.4324.1214.217.82

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue0.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.020.030.020.030.030.030.020.03
Gross Profit-0.02-0.03-0.02-0.03-0.03-0.03-0.02-0.03
Selling, General and Administrative Excl. Other4.865.545.094.524.013.853.912.40
Research and Development2.613.663.403.092.272.072.340.98
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-4.88-5.57-5.12-4.55-4.04-3.87-3.94-2.42
Interest Expense0.000.000.000.000.000.000.000.00
Unusual Expense0.07-0.000.01-0.00-0.010.01-0.000.02
Net Income Before Taxes-4.83-5.46-4.98-4.38-3.97-3.78-3.79-2.33
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-4.83-5.46-4.98-4.38-3.97-3.78-3.79-2.33
Net Income From Continuing Operations-4.83-5.46-4.98-4.38-3.97-3.78-3.79-2.33
Net Income-4.83-5.46-4.98-4.38-3.97-3.78-3.79-2.33
EPS (Recurring)-0.95-2.72-2.54-2.92-6.76-224.40-225.69-435.14
EPS (Basic, Before Extraordinaries)-0.96-2.72-2.54-2.92-6.74-224.52-225.68-437.19
EPS (Diluted)-0.96-2.72-2.54-2.92-6.74-224.52-225.68-437.19
EBITDA-4.86-5.54-5.09-4.52-4.01-3.85-3.91-2.40
Non-Operating Income (Expense)0.120.100.150.170.060.110.140.11
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense0.480.540.440.290.180.330.360.33
Shares Outstanding4.802.011.961.500.590.590.020.01
Market Capitalization18.069.499.898.494.235.430.130.17

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments18.7414.0610.6912.857.480.325.244.777.99
Short Term Receivables0.000.000.000.000.000.000.080.060.07
Inventories0.000.000.000.000.000.000.000.000.00
Other Current Assets1.260.870.590.521.020.000.060.160.17
Total Current Assets20.0114.9311.2913.378.500.325.384.988.22
Net Property, Plant & Equipment0.000.000.000.000.000.000.670.410.39
Total Investments and Advances0.000.000.000.000.000.000.090.090.09
Long-Term Note Receivable-----0.020.030.040.05
Intangible Assets0.380.480.580.700.810.910.000.000.00
Other Assets0.000.300.300.380.050.140.000.000.00
Total Assets20.3915.7112.1714.469.361.386.175.528.75
Short Term Debt Incl. Current Port. of LT Debt0.000.000.000.000.001.210.110.000.00
Accounts Payable1.260.910.530.610.920.000.050.240.49
Other Current Liabilities4.283.283.052.927.786.770.891.070.69
Total Current Liabilities5.554.183.583.538.707.991.051.311.18
Long Term Debt0.000.000.000.000.000.000.200.000.00
Provision for Risks Charges0.000.000.000.000.000.000.000.00-
Other Liabilities1.722.322.923.520.000.000.630.492.14
Total Liabilities7.276.506.517.058.707.991.881.803.32
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.000.00
Common Equity13.129.205.667.410.66-6.614.303.735.43
Total Shareholders Equity13.129.205.667.410.66-6.614.303.735.43
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity13.129.205.667.410.66-6.614.303.735.43
Total Liabilities & Stockholders Equity20.3915.7112.1714.469.361.386.175.528.75
Book Value Per Share8.761,260.187,028.634.4935.99-4,042.4314,090.68105,004.60166,060.09
Tangible Book Value Per Share8.501,194.016,304.764.07-8.30-4,600.8014,090.68105,004.60166,060.10
Full-Time Employees4544412142824
Price to Book Ratio0.630.020.02107.23265.475.173.312.104.06
Return on Assets-88.26-64.60-65.08-78.48-277.94-55.89-80.67-78.40-89.37
Return on Equity-142.71-121.13-132.57-231.77-807.04-117.32-117.62-122.20-122.30
Return on Invested Capital-121.42-97.83-152.97-126.16-3,268.81--105.03-150.14-144.50
Quick Ratio3.613.573.153.790.980.045.113.806.97
Current Ratio3.613.573.153.790.980.045.113.806.97

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-19.66-15.93-9.01-8.66-9.34-21.48-2.11-4.72-5.59
Depreciation0.100.100.100.100.100.100.100.230.13
Other Funds (Non Cash)1.470.941.010.620.5814.320.38-0.86-1.34
Funds from Operations-18.09-14.89-7.89-7.94-8.66-7.05-1.62-5.35-6.81
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital-0.801.24-0.000.10-0.091.330.28-0.360.23
Cash from Operating Activities-18.89-13.65-7.89-7.84-8.76-5.72-1.35-5.71-6.57
Capital Expenditures0.000.000.000.00-0.25-0.63-0.13-0.03-0.18
Net Assets From Acquisitions0.000.000.000.000.000.000.000.00-
Sale of Fixed Assets and Businesses0.000.000.000.000.000.000.000.000.00
Purchase or Sale of Investments-19.32-4.31-1.902.18-9.860.000.000.004.00
Purchase of Investments-35.45-12.36-17.34-18.04-9.860.000.00--0.01
Sale Or Maturity of Investments16.138.0515.4420.230.000.000.000.004.00
Other Uses0.000.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.000.00
Cash from Investing Activities-19.32-4.31-1.902.18-10.11-0.63-0.13-0.033.81
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock18.7918.7611.625.8314.8210.11-0.146.283.55
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.000.00
Sale of Common Pref Stock18.7918.7611.625.8314.8210.11-0.146.283.55
Proceedsfrom Stock Options18.5918.7611.625.8314.8210.11-0.140.000.00
Issuance or Reduction of Debt, Net0.000.000.000.000.003.480.92-0.150.00
Change in Long Term Debt0.000.000.000.000.000.000.00-0.150.00
Issuance of Long Term Debt0.000.000.000.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.000.00-0.150.00
Net Financing Active Other Cash Flow27.71-0.60-0.60-0.63-0.56-0.071.030.000.00
Other Financing Activities Uses-0.60-0.60-0.60-0.63-0.60-0.35-0.050.000.00
Cash from Financing Activities46.5018.1611.025.2014.2613.511.806.143.55
Exchange Rate Effect--0.00----0.37-0.320.35
Net Change in Cash8.300.201.23-0.46-4.607.160.330.081.13
Free Cash Flow-18.89-13.65-7.89-7.84-8.76-5.72-1.35-5.74-6.76
Preferred Dividends (Cash Flow)-0.000.000.00-0.000.000.000.00
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments33.1810.8014.0418.745.417.79
Short Term Receivables0.000.000.000.000.000.00
Inventories0.000.000.000.000.000.00
Other Current Assets1.220.841.291.260.600.69
Total Current Assets34.4011.6415.3320.016.028.48
Net Property, Plant & Equipment0.000.000.000.000.000.00
Total Investments and Advances0.000.000.000.000.000.00
Intangible Assets0.310.330.360.380.410.43
Other Assets0.040.000.000.000.000.00
Total Assets34.7511.9715.6920.396.428.91
Short Term Debt Incl. Current Port. of LT Debt0.000.000.000.000.000.00
Accounts Payable1.583.111.781.261.860.87
Other Current Liabilities3.203.503.574.283.903.46
Total Current Liabilities4.786.615.355.555.764.34
Long Term Debt0.000.000.000.000.000.00
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities1.271.421.571.721.872.02
Total Liabilities6.058.046.927.277.646.36
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity28.703.938.7713.12-1.212.55
Total Shareholders Equity28.703.938.7713.12-1.212.55
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity28.703.938.7713.12-1.212.55
Total Liabilities & Stockholders Equity34.7511.9715.6920.396.428.91
Book Value Per Share5.971.964.478.76-2.074.34
Tangible Book Value Per Share5.911.794.298.50-2.763.60
Full-Time Employees---4--
Price to Book Ratio0.631.080.75-6.991.660.92
Return on Assets-95.47-179.96-119.39-88.14-155.66-106.71
Return on Equity-143.02-579.57-232.69-142.53-655.97-244.36
Return on Invested Capital-16.83-138.92-56.81-33.35--147.97
Quick Ratio7.201.762.873.611.041.95
Current Ratio7.201.762.873.611.041.95

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income-4.83-5.46-4.98-4.39-3.97-3.77
Depreciation0.020.030.020.030.030.03
Other Funds (Non Cash)0.440.490.330.210.190.25
Funds from Operations-4.36-4.95-4.63-4.16-3.76-3.50
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-1.381.73-0.23-0.921.52-0.25
Cash from Operating Activities-5.74-3.21-4.86-5.08-2.24-3.75
Capital Expenditures0.000.000.000.000.000.00
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments-16.164.094.11-11.352.551.73
Purchase of Investments-21.12-1.00-0.98-12.360.000.00
Sale Or Maturity of Investments4.955.085.091.012.551.73
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities-16.164.094.11-11.352.551.73
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock-0.000.000.2118.59-0.000.00
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock-0.000.000.2118.59-0.000.00
Proceedsfrom Stock Options0.00-0.210.2118.59-0.000.00
Issuance or Reduction of Debt, Net0.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow28.17-0.15-0.15-0.15-0.15-0.15
Other Financing Activities Uses-0.15-0.15-0.15-0.15-0.15-0.15
Cash from Financing Activities28.16-0.150.0618.44-0.15-0.15
Exchange Rate Effect0.00-0.000.00---
Net Change in Cash6.270.72-0.692.000.16-2.17
Free Cash Flow-5.74-3.21-4.86-5.08-2.24-3.75

Revenue breakdown

Revenue split-

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-30-0.0M-536.44K
2026-10-15-0.0M-536.19K
2026-09-30-0.1M-542.36K
2026-09-15-0.1M-757.26K
2026-08-31-0.5M-726.78K
2026-08-14-0.1M-239.55K
2026-07-31-0.1M-237.78K
2026-07-15-0.2M-244.88K
2026-06-30-0.3M-242.69K
2026-06-15-0.0M-97.81K
2026-05-29-0.0M-96.23K
2026-05-15-0.1M-96.10K
2026-04-30-0.1M-98.52K
2026-04-15-0.1M-101.22K
2026-03-31-0.1M-100.47K
2026-03-13-0.0M-33.39K
2026-02-27-0.0M-53.48K
2026-02-13-0.0M-64.01K
2026-01-30-0.0M-372.04K
2026-01-15-0.0M-379.78K

Option chain

expiry 2026-11-12
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
No option chain for this symbol.

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-068-KCurrent report2026-11-05SEC
2026-11-0510-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-11-04EFFECTEffectiveness filing by commission orderSEC
2026-11-048-KCurrent report2026-11-04SEC
2026-11-04424B5SEC
2026-11-04424B5SEC
2026-10-28S-3Registration statement for specified transactions by certain issuers including face-amount certificate companiesSEC
2026-10-264/A2026-08-27SEC
2026-10-208-KCurrent report2026-10-20SEC
2026-10-148-KCurrent report2026-10-14SEC
2026-10-07SCHEDULE 13G/ASEC
2026-10-02DEF 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-11-12SEC
2026-09-25EFFECTEffectiveness filing by commission orderSEC
2026-09-25424B3SEC
2026-09-22PRE 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-11-12SEC
2026-09-228-KCurrent report2026-09-22SEC
2026-09-18S-3Registration statement for specified transactions by certain issuers including face-amount certificate companiesSEC
2026-09-10DNotice of sales of securities on Form D (Regulation D)SEC
2026-09-108-KCurrent report2026-09-08SEC
2026-09-014Statement of changes in beneficial ownership of securities2026-08-31SEC
2026-09-014Statement of changes in beneficial ownership of securities2026-08-31SEC
2026-09-014Statement of changes in beneficial ownership of securities2026-08-31SEC
2026-09-014Statement of changes in beneficial ownership of securities2026-08-31SEC
2026-08-284Statement of changes in beneficial ownership of securities2026-08-27SEC
2026-08-284Statement of changes in beneficial ownership of securities2026-08-27SEC
2026-08-288-KCurrent report2026-08-27SEC
2026-08-208-KCurrent report2026-08-20SEC
2026-08-148-KCurrent report2026-08-14SEC
2026-08-1410-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-07-16ARSAnnual report to security holders. 2025-12-31SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-08279.97K400
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
AIGH Capital Management LLC11.76%
Dauntless Investment Group, LLC10.96%
Ikarian Capital, LLC10.79%
Stonepine Capital Management, LLC10.17%
MILLENNIUM MANAGEMENT LLC5.73%
SummitTX Capital, L.P.5.11%
Woodline Partners LP3.90%
Aberdeen Group plc3.82%
Soleus Capital Management, L.P.3.71%
BOOTHBAY FUND MANAGEMENT, LLC3.05%

Funds

Fund% owned
abrdn World Healthcare Fund2.06%
abrdn Life Sciences Investors1.76%

OakChart. QNRX. Cached 15 minutes.